Full history for every metric is available with a Kvantra account
Singular Genomics Systems, Inc. (OMIC)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 1 | 3 | 3 |
| Operating profit | $m | -103 | -93 | |||||
| Net profit | $m | - | -12 | -29 | -99 | -88 | -95 | -86 |
| EPS reported | $ | -39.08 | -34.92 | |||||
| Operating cashflow per share | $ | -30.35 | -30.35 | |||||
| Capex per share | $ | 0.40 | 0.40 | |||||
| FCF per share | $ | -30.75 | -30.75 | |||||
| Free cash flow | $m | -75 | -81 | |||||
| Net debt | $m | -165 | -109 | |||||
| Book value equity | $m | 179 | 123 | |||||
| Book value per share | $ | 73.77 | 49.28 | |||||
| Number of shares | m | 2.43 | 2.5 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.19 | 0.41 | |||||
| P/S LTM | x | 11.50 | 19.04 | |||||
| P/FCF LTM | x | -0.45 | -0.63 | |||||
| EV/EBITDA LTM | x | -1.07 | 0.74 | |||||
| EV/Sales LTM | x | 31.79 | -21.72 | |||||
| Earnings Yield LTM | % | -283.16% | -195.28% | |||||
| FCF Yield | % | -222.83% | -159.27% | |||||
| Quality | ||||||||
| ROE | % | -52.97% | -43.17% | |||||
| ROIC | % | -40.32% | -40.32% | |||||
| Operating margin | % | -3531.5% | -3531.5% | |||||
| Gross margin | % | -19.17% | -19.17% | |||||
| FCF/Sales | % | -2563.3% | -2563.3% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +280.52% | +2.74% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.99 | -1.60 | |||||
| Net Debt/EBITDA | x | -0.68 | -0.68 | |||||
| EBIT/Net interest | x | -93.37 | -93.37 | |||||
| Net debt/market cap | % | -492.86% | -214.06% | |||||
| Net debt/Equity | x | -0.92 | -0.88 | |||||
| Gross debt/equity | x | 0.42 | 0.41 | |||||
Company overview
Singular Genomics Systems, Inc. is a life science technology firm focused on creating advanced next-generation sequencing and multiomics solutions. The company aims to provide researchers and clinicians with innovative tools to accelerate scientific discovery and medical advancements. Among its core products is the G4 Instrument, a compact next-generation sequencer designed to deliver genetic sequencing results, supported by a selection of complementary consumable kits. Singular Genomics also offers the PX Integrated Solution, a versatile multiomics platform that consolidates single-cell analysis, spatial analysis, genomics, and proteomics into a single, unified instrument. To ensure broad compatibility for the G4, the company maintains strategic partnerships with entities like Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics for the validation of their library preparation kits. Additionally, a collaboration with the Broad Institute of MIT and Harvard enables the G4's integration with the Terra data platform. Established in 2016, Singular Genomics Systems, Inc. is headquartered in La Jolla, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Singular Genomics Systems, Inc. (OMIC)
Singular Genomics Systems, Inc. is a life science technology firm focused on creating advanced next-generation sequencing and multiomics solutions. The company aims to provide researchers and clinicians with innovative tools to accelerate scientific discovery and medical advancements. Among its core products is the G4 Instrument, a compact next-generation sequencer designed to deliver genetic sequencing results, supported by a selection of complementary consumable kits. Singular Genomics also offers the PX Integrated Solution, a versatile multiomics platform that consolidates single-cell analysis, spatial analysis, genomics, and proteomics into a single, unified instrument. To ensure broad compatibility for the G4, the company maintains strategic partnerships with entities like Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics for the validation of their library preparation kits. Additionally, a collaboration with the Broad Institute of MIT and Harvard enables the G4's integration with the Terra data platform. Established in 2016, Singular Genomics Systems, Inc. is headquartered in La Jolla, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free